Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Early Neuropsychological Rehabilitation and Family Psychoeducation After Ischemic Stroke

1 settembre 2026 aggiornato da: Jordi Sanchez Monteagudo, Althaia Xarxa Assistencial Universitària de Manresa

Efficacy of Early Neuropsychological Rehabilitation and Family Psychoeducation After Ischemic Stroke: A Randomized 2×2 Factorial Clinical Trial With Blinded Outcome Assessment

Cognitive impairment and reduced quality of life are frequent consequences of ischemic stroke and can also affect family caregivers, who often assume caregiving responsibilities with limited preparation. Evidence regarding rehabilitation interventions initiated during the early poststroke period remains limited.

This randomized clinical trial evaluates two independent interventions initiated after baseline assessment and randomization, approximately 20 days after the index stroke: a structured computerized neuropsychological rehabilitation program for the patient and a structured psychoeducational program for the primary family caregiver. A 2×2 factorial design allows the main effect of each intervention to be estimated within a single sample and permits an exploratory assessment of their interaction.

The primary outcome is quality of life at 3 months after stroke, measured using the CAVIDACE total direct score and completed by a family informant. Secondary outcomes include cognitive performance, functional status, mood, and caregiver burden. Molecular biomarkers and acute structural neuroimaging variables are examined as exploratory outcomes.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Background and rationale

Cognitive deficits are frequent after ischemic stroke and may adversely affect functional recovery, quality of life, emotional well-being, and participation in rehabilitation. Although recovery trajectories vary considerably between individuals, the early poststroke period represents an important phase of cognitive, functional, and psychosocial adaptation. Evidence regarding structured cognitive rehabilitation initiated during this early period remains limited.

Stroke also has important consequences for family members and informal caregivers. Caregivers may experience substantial burden associated with functional dependence, cognitive and behavioral changes, emotional difficulties, and the demands of providing ongoing support. Structured psychoeducational interventions may help caregivers understand the consequences of stroke and develop appropriate strategies for supporting recovery and adaptation.

This trial evaluates both dimensions simultaneously by examining computerized neuropsychological rehabilitation directed at the patient and structured family psychoeducation directed at the primary family caregiver.

Procedures

Participants are recruited during the acute phase of ischemic stroke, within 96 hours of symptom onset. Baseline assessment of the primary outcome is performed approximately 20 days after the index stroke, before randomization and before either intervention begins. Randomization is performed after completion of this baseline assessment.

Allocation is stratified according to receipt of acute reperfusion therapy, defined as intravenous thrombolysis and/or mechanical thrombectomy versus no reperfusion treatment. Reperfusion status is used as a prespecified prognostic stratification factor. Randomization is implemented through the REDCap electronic data capture system using randomly permuted blocks of variable size. The allocation sequence is inaccessible to personnel responsible for recruitment and eligibility assessment, and the next treatment assignment cannot be anticipated.

Both intervention factors begin after randomization, approximately 20 days after the index stroke, and continue for approximately 12 weeks. The primary outcome assessment is scheduled at 3 months after stroke, corresponding to 90 days ±14 days. An optional 12-month follow-up constitutes an observational extension and is not part of the primary randomized trial analysis.

Participants allocated to computerized neuropsychological rehabilitation receive 24 sessions of structured computerized cognitive training using the Guttmann NeuroPersonalTrainer platform. Sessions last 45 minutes and are delivered twice weekly over approximately 12 weeks. The sequence and duration of the cognitive exercises are standardized, while task difficulty is individually adjusted by the platform according to previous performance. The intervention targets attention, processing speed, memory, executive functions, language, visuospatial abilities, and functional transfer of trained strategies.

Participants not allocated to computerized neuropsychological rehabilitation receive an active digital control condition consisting of simple recreational digital activities matched in duration and frequency. These activities do not incorporate adaptive difficulty, structured therapeutic progression, or cognitive performance feedback.

Primary family caregivers allocated to structured family psychoeducation receive six individual 45-minute sessions delivered by videoconference approximately every 2 weeks over 12 weeks. The program includes stroke education, the role of the family in recovery, emotional management, behavioral difficulties, cognitive restructuring, relaxation, self-compassion, mindfulness-based coping strategies, and behavioral activation. Caregivers are not trained in cognitive rehabilitation techniques in order to preserve the conceptual independence of the two factorial intervention components.

Primary family caregivers not allocated to structured psychoeducation receive a brief informational leaflet at the approximately 20-day visit after randomization. The leaflet provides general information about stroke and its physical, communicative, cognitive, emotional, and behavioral consequences, together with recommended educational resources. It does not include behavioral management strategies, structured psychoeducational techniques, or cognitive rehabilitation training.

All participants continue to receive usual poststroke clinical care. Physiotherapy, occupational therapy, speech therapy, convalescence care, and other rehabilitation services may be prescribed according to clinical indication and are recorded as co-interventions.

Outcomes and analysis

The primary outcome is the CAVIDACE total direct score at 3 months after stroke, completed by a family informant. The total direct score ranges from 0 to 192, with higher scores indicating better quality of life. The corresponding CAVIDACE score obtained approximately 20 days after stroke is used as the baseline covariate in the primary analysis.

Secondary outcomes are organized into two independent prespecified families. The family associated with computerized neuropsychological rehabilitation includes the global neuropsychological composite score, Modified Rankin Scale, Barthel Index, and Lawton-Brody Instrumental Activities of Daily Living Scale. The family associated with structured family psychoeducation includes the Zarit Burden Interview, Hospital Anxiety and Depression Scale Anxiety subscale, Hospital Anxiety and Depression Scale Depression subscale, and Beck Depression Inventory-II.

The primary analysis follows the intention-to-treat principle and uses an analysis of covariance model including the main effects of both intervention factors, baseline CAVIDACE, and the randomization stratum. The F1×F2 interaction is examined in a separate exploratory model.

Exploratory biological outcomes include brain-derived neurotrophic factor, glial fibrillary acidic protein, interleukin-6, C-reactive protein, and S100 calcium-binding protein B. Acute structural magnetic resonance imaging variables include lesion volume, lesion location, vascular territory, Oxfordshire Community Stroke Project classification, and apparent diffusion coefficient. These analyses are considered exploratory and hypothesis-generating.

A prespecified Statistical Analysis Plan defining the estimands, analysis models, handling of missing data, multiplicity, and sensitivity analyses was finalized and signed before database lock and before any comparative analysis of study outcomes.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

81

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Barcelona
      • Manresa, Barcelona, Spagna, 08243
        • Hospital Universitari Sant Joan de Déu de Manresa, Fundació Althaia

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • First-ever ischemic stroke, excluding transient ischemic attack
  • Age 18 years or older
  • Inclusion within 96 hours of symptom onset
  • Functional independence before the index stroke, defined as a prestroke Modified Rankin Scale score ≤1
  • Diagnosis of ischemic stroke classified according to the Oxfordshire Community Stroke Project as total anterior circulation infarction, partial anterior circulation infarction, posterior circulation infarction, or lacunar infarction
  • Capacity to provide written informed consent at enrollment or, in cases of temporary incapacity, availability of a legally authorized representative to provide consent on the participant's behalf, followed by participant re-consent if decision-making capacity is regained

Exclusion Criteria:

  • Previous neurological or psychiatric disease associated with cognitive impairment
  • Severe systemic disease
  • Life expectancy of less than 1 year
  • Severe stroke, defined as a National Institutes of Health Stroke Scale score >19 at admission
  • Alcohol or other substance abuse, excluding tobacco use
  • Clinically relevant aphasia preventing comprehension of neuropsychological test instructions, operationalized as a score <5 on the fluency subscale of the Western Aphasia Battery
  • Sensory impairment preventing valid neuropsychological assessment or use of the intervention materials, such as severe visual or hearing impairment
  • Functional illiteracy, defined as inability to read and understand simple written instructions

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione fattoriale
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Group 1: Control
Simple recreational digital activities matched to the computerized neuropsychological rehabilitation condition in session duration and frequency. The activities do not incorporate adaptive difficulty, structured therapeutic progression, or cognitive performance feedback.
A brief informational leaflet provided at the approximately 20-day visit after randomization. The leaflet includes general information about stroke and its physical, communicative, cognitive, emotional, and behavioral consequences, together with recommended educational resources. It does not include behavioral management strategies, structured psychoeducational techniques, or cognitive rehabilitation training.
Sperimentale: Group 2: Neuropsychological rehabilitation
A brief informational leaflet provided at the approximately 20-day visit after randomization. The leaflet includes general information about stroke and its physical, communicative, cognitive, emotional, and behavioral consequences, together with recommended educational resources. It does not include behavioral management strategies, structured psychoeducational techniques, or cognitive rehabilitation training.
Structured computerized cognitive training using the Guttmann NeuroPersonalTrainer platform. The intervention comprises 24 sessions of 45 minutes, delivered twice weekly over approximately 12 weeks, starting after randomization approximately 20 days after the index stroke. The sequence and duration of cognitive exercises are standardized, while task difficulty is individually adjusted by the platform according to previous performance.
Sperimentale: Group 3: Family psychoeducation
Simple recreational digital activities matched to the computerized neuropsychological rehabilitation condition in session duration and frequency. The activities do not incorporate adaptive difficulty, structured therapeutic progression, or cognitive performance feedback.
Six individual 45-minute sessions delivered by videoconference to the primary family caregiver approximately every 2 weeks over 12 weeks. The program covers stroke education, the role of the family in recovery, emotional management, behavioral difficulties, cognitive restructuring, relaxation, self-compassion, mindfulness-based coping strategies, and behavioral activation. Caregivers are not trained in cognitive rehabilitation techniques.
Sperimentale: Group 4: Combined intervention
Structured computerized cognitive training using the Guttmann NeuroPersonalTrainer platform. The intervention comprises 24 sessions of 45 minutes, delivered twice weekly over approximately 12 weeks, starting after randomization approximately 20 days after the index stroke. The sequence and duration of cognitive exercises are standardized, while task difficulty is individually adjusted by the platform according to previous performance.
Six individual 45-minute sessions delivered by videoconference to the primary family caregiver approximately every 2 weeks over 12 weeks. The program covers stroke education, the role of the family in recovery, emotional management, behavioral difficulties, cognitive restructuring, relaxation, self-compassion, mindfulness-based coping strategies, and behavioral activation. Caregivers are not trained in cognitive rehabilitation techniques.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Quality of life (CAVIDACE total direct score)
Lasso di tempo: 3 months post-stroke (day 90 ± 14 days)
The CAVIDACE scale (Quality of Life in Acquired Brain Injury) is completed by a family informant. The total direct score ranges from 0 to 192, with higher scores indicating better quality of life. The corresponding CAVIDACE score obtained approximately 20 days after stroke is used as the baseline covariate in the primary analysis.
3 months post-stroke (day 90 ± 14 days)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Global neuropsychological composite score
Lasso di tempo: 3 months post-stroke (90 days ±14 days)
The global neuropsychological composite score is calculated as the unweighted mean of standardized z scores across five cognitive domains: attention and processing speed, memory and learning, language, executive functioning, and visuospatial functioning. Individual neuropsychological test scores are standardized using the corresponding normative data. At least three valid cognitive-domain scores are required to calculate the composite. Because the composite consists of standardized z scores, it has no fixed theoretical minimum or maximum. Higher scores indicate better global cognitive performance.
3 months post-stroke (90 days ±14 days)
Modified Rankin Scale
Lasso di tempo: 3 months post-stroke (90 days ±14 days)
The Modified Rankin Scale assesses global disability after stroke on an ordinal scale ranging from 0 to 6. A score of 0 indicates no symptoms, whereas a score of 6 indicates death. Higher scores indicate greater disability and a worse outcome.
3 months post-stroke (90 days ±14 days)
Barthel Index
Lasso di tempo: 3 months post-stroke (90 days ±14 days)
The Barthel Index assesses independence in basic activities of daily living. The total score ranges from 0 to 100. Higher scores indicate greater functional independence and a better outcome.
3 months post-stroke (90 days ±14 days)
Lawton-Brody Instrumental Activities of Daily Living Scale
Lasso di tempo: 3 months post-stroke (90 days ±14 days)
The Lawton-Brody Instrumental Activities of Daily Living Scale assesses independence in instrumental activities of daily living. The 8-item version used in this study ranges from 0 to 8. Higher scores indicate greater independence and a better functional outcome.
3 months post-stroke (90 days ±14 days)
Zarit Burden Interview, 22-item version
Lasso di tempo: 3 months post-stroke (90 days ±14 days)
The 22-item Zarit Burden Interview assesses perceived caregiver burden. Each item is rated from 0 to 4, yielding a total score ranging from 0 to 88. Higher scores indicate greater perceived caregiver burden and a worse outcome.
3 months post-stroke (90 days ±14 days)
Hospital Anxiety and Depression Scale - Anxiety Subscale (HADS-A)
Lasso di tempo: 3 months post-stroke (90 days ±14 days)
The Hospital Anxiety and Depression Scale Anxiety subscale consists of 7 items and yields a total score ranging from 0 to 21. Higher scores indicate greater severity of anxiety symptoms and a worse outcome.
3 months post-stroke (90 days ±14 days)
Hospital Anxiety and Depression Scale - Depression Subscale (HADS-D)
Lasso di tempo: 3 months post-stroke (90 days ±14 days)
The Hospital Anxiety and Depression Scale Depression subscale consists of 7 items and yields a total score ranging from 0 to 21. Higher scores indicate greater severity of depressive symptoms and a worse outcome.
3 months post-stroke (90 days ±14 days)
Beck Depression Inventory-II
Lasso di tempo: 3 months post-stroke (90 days ±14 days)
The Beck Depression Inventory-II consists of 21 items and yields a total score ranging from 0 to 63. Higher scores indicate greater severity of depressive symptoms and a worse outcome.
3 months post-stroke (90 days ±14 days)

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Biomarker concentrations (BDNF, GFAP, IL-6, CRP, and S100B)
Lasso di tempo: Acute hospitalization (≤96 hours after stroke), approximately 20 days after stroke, and 3 months after stroke (90 days ±14 days); optional observational assessment at 12 months
Exploratory longitudinal biomarker outcomes including brain-derived neurotrophic factor, glial fibrillary acidic protein, interleukin-6, C-reactive protein, and S100 calcium-binding protein B. Biomarker concentrations are examined in relation to clinical and cognitive recovery.
Acute hospitalization (≤96 hours after stroke), approximately 20 days after stroke, and 3 months after stroke (90 days ±14 days); optional observational assessment at 12 months
Acute structural MRI lesion characteristics
Lasso di tempo: Acute hospitalization (≤96 hours after stroke)
Exploratory variables derived from acute structural magnetic resonance imaging include lesion volume, lesion location, vascular territory, Oxfordshire Community Stroke Project classification, and apparent diffusion coefficient.
Acute hospitalization (≤96 hours after stroke)
Montreal Cognitive Assessment (MoCA)
Lasso di tempo: Acute hospitalization (≤96 hours), approximately 20 days after stroke, 3 months after stroke, and optional observational follow-up at 12 months.
The Montreal Cognitive Assessment evaluates global cognitive performance. Total scores range from 0 to 30, with higher scores indicating better global cognitive performance.
Acute hospitalization (≤96 hours), approximately 20 days after stroke, 3 months after stroke, and optional observational follow-up at 12 months.
Functional Ambulation Category (FAC)
Lasso di tempo: Acute hospitalization (≤96 hours), approximately 20 days after stroke, 3 months after stroke, and optional observational follow-up at 12 months.
The Functional Ambulation Category assesses functional walking ability. Scores range from 0 to 5, with higher scores indicating greater independence in ambulation.
Acute hospitalization (≤96 hours), approximately 20 days after stroke, 3 months after stroke, and optional observational follow-up at 12 months.
Hessisch Oldendorf Risk of Falling Scale (HOSS)
Lasso di tempo: Acute hospitalization (≤96 hours), approximately 20 days after stroke, 3 months after stroke, and optional observational follow-up at 12 months.
The Hessisch Oldendorf Risk of Falling Scale assesses risk of falling. Total scores range from 0 to 22, with higher scores indicating greater risk of falling.
Acute hospitalization (≤96 hours), approximately 20 days after stroke, 3 months after stroke, and optional observational follow-up at 12 months.
Depression Signs Scale (ESD)
Lasso di tempo: Acute hospitalization (≤96 hours), approximately 20 days after stroke, 3 months after stroke, and optional observational follow-up at 12 months.
The Depression Signs Scale (Escala de Signes de Depressió), developed by the Catalan Agency for Health Quality and Assessment, comprises 6 dichotomously scored items and yields a total score ranging from 0 to 6. Higher scores indicate a greater number of observed signs suggestive of mood disturbance.
Acute hospitalization (≤96 hours), approximately 20 days after stroke, 3 months after stroke, and optional observational follow-up at 12 months.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Jordi Sanchez Monteagudo, Hospital Universitari Sant Joan de Déu de Manresa, Fundació Althaia

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

19 novembre 2025

Completamento primario (Stimato)

25 novembre 2026

Completamento dello studio (Stimato)

27 luglio 2027

Date di iscrizione allo studio

Primo inviato

26 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

26 agosto 2026

Primo Inserito (Effettivo)

28 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

1 settembre 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CER-21-39

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Following publication of the primary trial results, deidentified individual participant data underlying the published analyses, together with the corresponding data dictionary where applicable, may be made available upon reasonable request. Access will be subject to approval by Fundació Althaia and compliance with applicable ethical, institutional, informed-consent, and data-protection requirements.

Periodo di condivisione IPD

Beginning after publication of the primary trial results.

Criteri di accesso alla condivisione IPD

Access may be granted following a reasonable scientific request, review and approval by Fundació Althaia, and compliance with applicable ethical, institutional, informed-consent, and data-protection requirements.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .